ONCOlog has filed for bankruptcy

Since the autumn of 2012, the Board of ONCOlog has worked to find buyers for the
sale of the entire company or its assets. However, these efforts have not been
successful and the ONCOlog Board has therefore not seen any alternative left but
to apply for the company to be declared bankrupt.
Allenex owns 14.9% of ONCOlog, but has since mid-2011 changed its focus to
include the transplantation area only. Allenex has since this strategic shift
not financed ONCOlog in any way. Therefore, the ONCOlog bankruptcy will not have
any effect on Allenex` financial results. This is due to the fact that the
Allenex holding in ONCOlog is already valued at zero and that no other
commitments exist.

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on May 08, 2013, at 12.45 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the
Allenex group.